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Sineoculis homeobox homolog 1 (Six1), normally a developmentally restricted transcriptional regulator, is frequently
dysregulated in mutiple cancers. Increasing evidences show that overexpression of Six1 plays a key role in tumorigenesis.
However, the Six1 expression status and its relationship with the clinicopathological characteristics in prostate cancer
were unclear. In this study, the mRNA and protein levels of Six1 in prostate cancer tissues and normal prostate tissues
were evaluated. The clinicopathological significance of Six1 was investigated by immunohistochemistry (IHC) on a
prostate cancer tissue microarray. The cut-off score for high expression of Six1 was determined by the receiver-operating
characteristic (ROC) analysis. The correlation between Six1 protein expression and clinicopathological characteristics of
prostate cancer was analyzed by Chi-square test. Increased expression of Six1 protein was observed in the majority of
prostate cancer, compared with their paired adjacent normal prostate tissues. When Six1 high expression percentage
was determined to be above 55 % (area under ROC curve = 0.881, P = 0.000), high expression of Six1 was observed in
55.6 % (80/144) of prostate cancer tissues and low expression of Six1 was observed in all normal prostate tissues by IHC.
Increased expression of Six1 in patients was correlated with high histological grade (χ2 = 58.651, P = 0.00), advanced
clinical stage (χ2 = 57.330, P = 0.000), high Gleason score (χ2 = 63.480, P = 0.000), high primary tumor grade (χ2 = 57.330,
P = 0.000) and positive regional lymph node metastasis (χ2 = 19.294, P = 0.000). Furthermore, univariate and multivariate
survival analysis suggested that Six1 was an independent prognostic indicator for overall survival (P < 0.05). This study
suggests that Six1 could be served as an additional biomarker in identifying prostate cancer patients at risk of tumor
progression, might potentially be used for predicting survival outcome of patients with prostate cancer.
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Current diagnosis for prostate cancer includes digital
rectal examination (DRE), prostate-specific antigen (PSA)
and needle biopsy [1]. The appearance of prostate-specific
antigen (PSA) testing has revolutionarily improved early
prostate cancer detection. If rising PSA levels are detected,
a needle biopsy of the prostate is recommended to inspect
for histologic evidence of prostate cancer. If cancer is
inspected, the patient can choose either active surveillance
or one of several given treatment options, such as surgery,
radiotherapy, or brachytherapy. However, current reports
have raised concern over the efficacy of PSA testing. The
U.S. prostate cancer screening trial report found that the
mortality caused by prostate cancer was not reduced by
PSA screening [2]. These studies suggested that PSA* Correspondence: weimin78@126.com; Wenlimat@126.com
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prostate cancer; therefore, many patients accepted over-
treatment. As a result of these kind reports, the U.S. Pre-
ventive Services Task Force recommended to stop routine
screening by PSA testing on all males [3]. Regardless of
how much controversy about the PSA screening, there is
an agreement that a definitive test is needed to distinguish
patients with aggressive prostate cancer from the patients
that have latent or indolent prostate cancer. Therefore, a
critical question in the clinical activity of prostate cancer
is how to distinguish the patients with indolent prostate
cancer from patients with highly aggressive prostate can-
cer who would benefit from definitive treatment.
Homeobox genes encode transcription factors that are
essential for the development of numerous organs and
control processes such as proliferation, apoptosis, migra-
tion, and invasion [4–7]. The Six1 homeoprotein, a
member of the Six family of homeodomain transcriptionicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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including breast [8–10], rhabdomyosarcomas [11–13], he-
patocellular carcinomas [14], ovarian [15] and Wilms
tumors [16]. Recent evidence demonstrates that Six1
plays a role in cellular migration and invasion during
embryogenesis [4, 17–20] and in breast cancer [21, 22]
through a mechanism that may involve an EMT, which
was associated with increased TGF-β receptor type I
(TβRI) expression and Smad-dependent transforming
growth factor-beta (TGF-β) signaling. In addition, Six1
overexpression enhances lymph node metastasis by in-
creasing VEGF-C depending on TGF-β signaling in cer-
vical cancer [23–26]. Forementioned studies suggested
that Six1 enhances cancer cell proliferation and shortens
survival and its overexpression in immortalized mammary
epithelial cells induces EMT, leading to highly aggressive
and invasive tumors when transplanted into nude mice [7].
Noteworthy, HD Jin et al. reported that Six1 overex-
pression positively correlated with clinical stage, lymph
node metastasis, overall survival (OS) and disease-free
survival (DFS) rates of patients with breast cancer.
Moreover, patients with high Six1 expression had poorer
prognosis than those with low Six1 expression in late
stage breast cancer cases [27]. However, the relationship
between Six1 and the clinicopathological characteristics
of prostate cancer has not previously been examined.
Materials and methods
Patient specimens and prostate cancer cohorts
A total of 144 paraffin-embedded tissues diagnosed from
2002 to 2012 were retrieved for tissue microarray (TMA)
construction and immunohistochemistry analysis. All the
samples were collected from the Department of Urology,
Nanfang Hospital (Guangzhou, China). The samples se-
lected were pathologically diagnosed with prostate cancer,
having received no prior chemotherapy or radiotherapy
before surgery. Ages of the 144 patients with prostate
cancer varied from 44 to 77 years (median, 65 years),
clinicopathological features of patients including age at
diagnosis, histologic grade, clinical stage, gleason score
and pTNM stages. Written informed consent was ob-
tained from all patients for use of the tissue samples
and clinical records. The study protocol was performed
under the approval by the Ethic Committee of the Nan-
fang Hospital. All cases were evaluated by experienced
pathologists for histopathological grading.
Quantitative real-time PCR
qRT-PCR was performed to determine the expression of
Six1 messenger RNA (mRNA). Briefly, we isolated total
RNAs from frozen tissues using TRIzol Reagent accord-
ing to the manufacturer’s protocol (Life Technologies)
and reverse transcribed to generate cDNA (PrimeScript
RT-PCR Kit, Takara Bio). β-Actin was used as an internalcontrol. The levels of mRNA encoding were quantified by
real-time PCR with the Applied Biosystems 7500 Fast
Real-Time PCR System using SYBR Premix Ex Taq (Ap-
plied Takara Bio). The sequences of the primers were as
follows: Six1 forward 5’- TTCTCGCCTCACAACCACC
CCA-3’ and reverse 5’-TACCACTCCCGCAGGACACC
CC-3’ and β-actin forward 5’-TGGCACCCAGCACAATG
AA-3’ and reverse 5’-CTAAGTCATAGTCCGCCTAGAA
GCA-3’. The PCR conditions were as following proce-
dures: initial step 95 °C for 2 min, followed by 35 cycles of
95 °C for 30 s, 56 °C for 30 s, and 72 °C for 2 min and a
final elongation step of 72 °C for 5 min. All qRT-PCRs
were repeated three times. Relative quantification of
Six1 mRNA expression was calculated using the 2−ΔΔCT
method.
Western blotting analysis
Total proteins from 8 pairs of fresh prostate cancer
and adjacent normal tissues were extracted by radio-
immunoprecipitation assay (RIPA) buffer containing
1 mM phenylmethanesulfonyl fluoride (PMSF) (Beyotime,
Haimen, China). After centrifugation, supernatant was col-
lected and treated with BCA Protein Assay Kit (Beyotime,
Haimen, China). The protein concentration was then mea-
sured at 562 nm -by the TECAN Infinite 200 microplate
reader (TECAN, Switzerland). Tissue homogenates (35 μg
protein for each sample) were separated by 10 % sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), and the resolved proteins were transferred onto a
polyvinylidene difluoride (PVDF) membrane (Millipore,
USA) by a Trans-Blot SD Semi-dry transfer cell machine
(Bio-Rad, USA). After the blots were washed with 1 ×
TBST buffer (10 mM Tris-HCl [pH 7.6], 150 mM NaCl,
and 0.05 % Tween-20), the membranes were blocked over-
night with 5 % skim milk and incubated with the appropri-
ate primary antibody at room temperature for 2 h.
Polyclonal rabbit anti-human antibody against Six1 (Atlas
antibody, Sweden, 1:500), and monoclonal rabbit anti-
human antibody against β-actin (Cell Signaling Technol-
ogy, Danvers, MA, USA, 1:3000) were used for detecting
the protein level of Six1 and β-actin in each sample. The
membranes were then washed by 1 × TBST, primary
antibodies were detected with goat anti-rabbit IgG con-
jugated to horseradish peroxidase (HRP) (Santa Cruz
Biotechnology, Cal, USA, 1:5000), and the bands were
detected by BeyoECL Plus Kit (Beyotime, Haimen,
China). Finally, the results of western blotting were vi-
sualized by the Image Station 4000R PRO scanner
(CareStream Health, Rochester, NY, U.S.A.).
Tissue microarray (TMA) construction and
immunohistochemistry (IHC)
Representative sections of prostate cancer or normal
prostate tissue in the pre-existing paraffin-embedded
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H&E staining slides. The TMA was constructed by using
a needle to punch a 1.5 mm diameter cylinder in the
representative section of each block, and placing the cyl-
inders into an array on a recipient paraffin block. 5 μm
thick multiple sections were cut from the TMA block
and mounted on microscope slides for immuohisto-
chemistry analysis. The TMA consisted of a total of 144
cases of prostate cancer and 10 cases of normal control
paraffin-embedded tissue. Clinical characteristic about
the patients was summarized in Table 1. The TMA slide
was dried overnight at 37 °C, deparaffinized in xylene,
rehydrated through graded alcohol, and then immersed
in 3 % hydrogen peroxide for 20 min to block the en-
dogenous peroxidase activity, and antigen-retrieved by
microwave heating with sodium citrate buffer (pH = 6.0)
at 100 °C for 30 min. Then the slides were pre-incubated
with 10 % normal goat serum at room temperature for
30 min to reduce nonspecific reaction. The primary
rabbit anti-Six1 polyclonal antibody (Atlas antibody,
Sweden) was diluted (1:1000) with 1 × phosphate buffered
saline (PBS) and applied overnight in a humidity chamber
at 4 °C. The slide was sequentially incubated with a polymerTable 1 Association of Six1 expression with patients’
clinicopathologic features in prostate cancer
Six1 protein
Variable All Cases Low High χ2 P valuea
Ageb
≤65 68 31 37 0.794 0.068
>65 76 33 43
Histological grade
G1 + G2 77 57 20 58.651 0.000
G3 67 7 60
Clinical stage
I + II 40 38 2 57.330 0.000
III + IV 104 26 78
Gleason score
1–7 54 47 7 63.480 0.000
8–10 90 17 73
pT status
T1 + T2 40 38 2 57.330 0.000
T3 + T4 104 26 78
pN status
N0 107 59 48 19.294 0.000
N1 + N2 37 5 32
pM status
M0 105 48 57 0.253 0.615
M1 39 16 23
aChi-squared test
bMean ageperoxidaselabeled secondary antibody (ZSGB-Bio, Beijing,
China) for 30 min at room temperature, and then stained
with DAB Horseradish Peroxidase Color Development Kit
(Beyotime, Haimen, China). Finally, the sections were coun-
terstained by hematoxylin. Known IHC positive slide was
used as a positive control, and phosphate buffered saline re-
placed anti-Six1 primary antibody was used as a control.
Evaluation of IHC
Immunoreactivity for the Six1 protein was scored by a
semi-quantitative method by recording the proportion of
positive tumor cells over the total number of tumor
cells. Scores were assigned by using 5 % increments
(0, 5…100 %). The reproducibility of the scoring method
between pathologists has been described previously for
TMAs [28–31]. The scores were accepted if two of the
three investigators (M.W, R.S and J.Z) agree with the
values. Otherwise, the values were re-estimated until a
consensus was reached. Our conclusions were in complete
agreement in 80 % of the cases, which indicated that the
scoring method was highly reproducible.
Selection of Cut-off scores using receiver- operating
characteristic (ROC) curves
Receiver operating characteristic curve analysis was
utilized to determine the cut-off score by using the 0,
1-criterion [32]. At the Six1 score, the sensitivity and
specificity for each outcome under study was plotted,
thus generating various ROC curves. The score was se-
lected as the cut-off score, which was closest to the
point with both maximum sensitivity and specificity.
Tumors designated as “low” for Six1 were those with
scores below and equal to the cut-off value, whereas
“high” tumors were those with scores above the value
[29]. In order to perform ROC curve analysis, the clinico-
pathological features were dichotomized: age (≤65 or >65),
histological grade (low [G1 +G2] or high G3), clinical stage
([I + II] or above [III + IV]), Gleason stage (1–7 or 8–10),
T stage (early [T1 + T2] or late [T3 + T4]), N stage (N0 [no
lymph node involvement] or N1 +N2 [any lymph node in-
volvement]), M stage (M0 [no distant metastasis] or M1
[distant metastasis]).
Statistical analysis
Statistical analysis was performed by using the SPSS stat-
istical software program (standard version 18.0; SPSS,
Chicago, USA). The relationship between Six1 protein
expression and clinicopathological data of Prostate can-
cer patients was estimated using the χ2 test. ROC curve
analysis was applied to determine the cut-off score for
Six1 positivity, and the areas under curves (AUCs) were
then calculated. The association between survival and
each variable was determined with the Kaplan-Meier
method (the log-rank test). Multiple Cox proportional
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pendent prognostic factors. P < 0.05 (two-tailed) denotes
the presence of a statistically significant difference.
Results
The expression level of Six1 in prostate cancer and
adjacent normal prostate tissues detected by western
blotting and IHC
In this study, the protein and/or mRNA expression of
Six1 was first examined by Western blotting and/or
qRT-PCR in 8 pairs of primary prostate cancer and adja-
cent normal prostate tissues. A significantly increase in
both protein and mRNA expression of Six1 was detected
in prostate cancer tissues compared to adjacent nontu-
morous tissues (Fig. 1a and b). For Six1 IHC staining in
prostate cancer tissues and normal prostate tissues, im-
munoreactivity was seen primarily in the cytoplasm and
perinucleus of prostate cancer cells (Fig. 1). Six1 expres-
sion could be evaluated informatively in 144 prostate
cancer cases by the TMA constructed previously and in
10 normal prostates. Immunoreactivity ranged from 0 toFig. 1 Expression of Six1 in prostate cancer tissues and normal prostate tis
mRNA expression of Six1 normalized to β-actin was calculated (n = 8), ★ in
examined by western blotting. Micrographs showed weak (c, c), moderate
well as low (f, f) expression of Six1 in normal prostate tissues (upper magn100 %. According to ROC analysis, expression percent-
age for Six1 above the critical value 55 % was defined as
high expression. The high expression of Six1 was de-
tected in 80 ⁄ 144 (55.6 %) of prostate cancer cases. The
decreasing frequency of Six1 high expression was de-
tected in normal prostate tissues (Fig. 1).
Selection of Six1 cut-off scores
The ROC for each clinicopathological parameter (Fig. 2)
clearly show the point on the curve closest to (0.0, 1.0)
which maximizes both sensitivity and specificity for the
outcome. The analysis of ROC for each clinicopathologi-
cal feature and Six1 expression (AUC = 0.674, P = 0.001)
is carried out to evaluate the patients’ survival status
(Fig. 3). The cut-off score was determined to be above
55 % for Six1 high expression. Tumor tissues with scores
above the determined cut-off values were considered high
expression of Six1 protein leading to the greatest number
of tumor cases correctly classified as having or not having
the clinical outcome. The corresponding AUCs (95 %
confidence interval [CI]) are showed in Table 2.sues detected by western blotting and immunochemistry. a Relative
dicates P < 0.05. b Expressions of Six1 protein in 8 paired tissues were
(d, d), and strong (e, e) staining of Six1 in prostate cancer tissues, as
ification × 100, lower panel: magnification × 400.)
Fig. 2 Determination of the cutoff value of high Six1 expression in prostate cancer tissues by ROC curves. The sensitivity and 1-specificity were
plotted for each clinical characteristic, including age (a), pathological grade (b), clinical stage (c), Gleason grade (d), pT status (e), pN status (f),
pM status (g)
Fig. 3 Receiver–operator curve (ROC) analysis for different clinicopathological parameters and Six1 expression was used to evaluate the survival
status. clinical stage (AUC = 0.626, P = 0.019), Gleason_score (AUC = 0.643, P = 0.008), T stage (AUC = 0.626, P = 0.019), N stage (AUC = 0.644,
P = 0.007), Six1 expression (AUC = 0.674, P = 0.001) implied significant statistical associations with the survival
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Table 2 Area under the ROC curve values for each
clinicopathological feature
Feature AUC (95 % CI) p value
Age 0.531 0.518
Histological grade 0.881 0.000
Clinical stage 0.869 0.000




AUC, Area under the curve; CI, Confidence interval
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clinicopathological parameters of prostate cancer
Six1 protein overexpression was significantly correlated
with histological grade, clinical stage, Gleason score, pri-
mary tumor statues and regional lymph node metastasis
of prostate cancer (P < 0.001). However, Six1 proteinTable 3 Univariate and Multivariate Analysis of Different Prognostic
Univariate analysisa





G1 + G2 77 106.956
G3 67 99.493
Clinical stage 9.
I + II 40 114.868





T1 + T2 40 114.868
T3 + T4 104 99.086
pN status 13
N0 107 107.933







HR indicates hazards ratio; CI indicates confidence interval
aLog-rank test; bCox regression model; cMean ageexpression was not related with patient age, distant me-
tastasis in prostate cancer (P > 0.05) (Table 1). For histo-
logical grades, the high expression rate of Six1 protein
was significantly higher in late grade (G3) prostate
cancers (89.6 %, 60/67) than in early histological grade
cases (G1 +G2) (26.0 %, 20/77) (P < 0.001). Similarly, the
high expression rate of Six1 protein was higher in breast
cancers with high Clinical stage (75.0 %, 78/104)
compared with those with low Clinical stage (0.5 %, 2/40)
(P < 0.001). The high expression rate of Six1 protein was
significantly higher in high Gleason score (8–10) prostate
cancers (81.1 %, 73/90) than in low Gleason score cases
(1–7) (13.0 %, 7/54) (P < 0.001). The high expression
rate of Six1 protein was 75.0 % (78/104) in high pT grade,
which was significantly higher than in low pT grade
(0.5 %, 2/40) (P < 0.001). Meanwhile, the high expression
rate of Six1 protein was significantly higher
in high pN grade (N1 + N2) prostate cancers (81.1 %,
73/90) than in low pN grade cases (N0) (13.0 %, 7/54)
(P < 0.001).Features in 144 Patients with prostate cancer
Multivariate analysisb
P value HR (95 % CI) P value
487 0.011 2.220 (1.146–4.300) 0.018
312 0.038 0.696 (0.335–1.446) 0.331
381 0.002 1.369 (0.312–6.004) 0.677
273 0.002 1.246 (0.391–3.969) 0.710
381 0.002 1.369 (0.312–6.004) 0.677
.772 0.000 1.710 (0.803–3.642) 0.164
529 0.216 1.162 (0.554–2.437) 0.692
.051 0.000 3.434 (1.168–10.100) 0.025
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protein expression and prostate patients’ survival
In univariate analysis, Kaplan–Meier survival curves and
the P-values for these curves were determined by log-rank
method. Above all, to confirm the representativeness of the
prostate cancer in the study, we analyzed established prog-
nostic factors of patient survival. The univariate analysis
demonstrated a significant impact of well-known clinico-
pathological prognostic parameters, such as histolotical
grade, clinical stage, Gleason score, pT status, pN status
and Six1 expression on patient overall survival (Table 3).
Assessment of survival in all specimens demonstrated that
increased expression of Six1 protein was associated with
worse overall survival (P < 0.001, Fig. 4), and the mean
survival time for patients with tumors having low Six1
expression was 87.4 months compared to 42.8 months for
patients with tumors having high Six1 expression (Table 3).
Independent prognostic factors of prostate cancer:
multivariate survival analysis
A multivariate analysis based on the Cox proportional
hazard model was applied to test the independent value
of each parameter predicting overall survival (Table 3).
Expressions of Six1 as well as other clinicopathological
features that were significant by univariate analysisFig. 4 Kaplan–Meier survival analysis of Six1 expression in 144 patients of p
patient overall survival: low expression, n = 64 and high expression, n = 80(histological grade, clinical stage, Gleason score, pT stage
and pN stage) were included in multivariate analysis.
The expression of Six1 was found to be an independent
prognostic factor for adverse overall survival (relative risk,
2.322; 95 % CI, 1.163-4.636; P = 0.017). Of the other pa-
rameters, Clinical stage (P = 0.044), pT stage (P = 0.044)
were demonstrated as well an independent prognostic fac-
tor for overall survival.
Discussion
Prostate cancer is one of the most frequently diagnosed
malignancies and second only to lung and bronchus can-
cer in men worldwide. Approximately 258,400 men dead
from this disease in 2008 [33]. At current rates of diag-
nosis, one-sixth of men will be diagnosed with prostate
cancer during his lifetime [34]. From the clinical per-
spective, the tumors in different patients must be vary-
ing in the molecular level and the aim of personalized
medicine is to generate individual risk profiles from the
primary prostate cancer that could distinguish high-risk
individuals who should accept aggressive therapeutic
treatment and clinical follow-up from those who have
indolent prostate cancer to avoid these individuals from
undergoing overtreatment. Recently, several studies have
investigated molecular and genetic characteristics ofrostate cancer (log-rank test). Relationship of Six1 expression and
(P < 0.001)
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biomarkers [35–37].
It was reported that in multiple types of human can-
cer, such as breast, rhabdomyosarcomas, hepatocellular
carcinomas, ovarian, and Wilms tumors, overexpression
of Six1 was frequently identified [8–16]. In the study, we
investigated the expression patterns of Six1, by Western
blotting using fresh prostate tissues, and by IHC using
TMA containing a large cohort of prostate tumor
samples (144 cases) with complete clinicopathological
and follow-up data. Western blotting revealed that up-
regulation expression of Six1 was detected in prostate
cancer, when compared with adjacent normal prostate
tissues. Moreover, the IHC results demonstrated that
an increasing expression of Six1 was observed from
low malignant tumors to high malignant tumors. Six1
immunoreactivity was assessed using a scoring method de-
scribed in previous study [29]. The reliability of this scoring
method for Six1 was assessed by three investigators and
was again found to be highly reproducible. To select the
IHC cut-off scores for Six1 positivity, ROC analysis was
carried out for each of the clinicopathological parameters,
including age, histological grade, clinical stage, Gleason
score, pTNM stage. ROC analysis for different clinicopath-
ological features and Six1 expression was also used to
evaluate the survival status. Six1 expression demonstrated
significant statistical associations with the survival status of
patients with prostate cancer. These data provided evi-
dence that the unregulated expression of Six1 played an
important role in tumorigenic process of multiple human
cancers, including prostate cancer.
In summary, the study suggests that increased expres-
sion of Six1 may represent a more aggressive status of
prostate cancer. In addition, these results show that in-
creased expression of Six1 predicts poorer outcome of
the cancer for the patients compared to those patients
with decreased expression of Six1. Further studies are
needed to clarify the precise mechanism of Six1 in pros-
tate cancer and to develop potential therapies targeting
Six1 in prostate cancer.
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